Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 2/20 | 0.41 |
| ▸ | AKT1 | P31749 | 1/20 | 0.41 |
| ▸ | MTOR | P42345 | 1/20 | 0.41 |
| ▸ | ACACB | O00763 | 1/20 | 0.40 |
| ▸ | EGFR | P00533 | 2/20 | 0.39 |
| ▸ | ITK | Q08881 | 2/20 | 0.39 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | KRAS | P01116 | 1/20 | 0.36 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.36 |
| ▸ | FFAR2 | O15552 | 2/20 | 0.36 |
| ▸ | NAMPT | P43490 | 1/20 | 0.36 |
| ▸ | GRM5 | P41594 | 2/20 | 0.35 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2227691 | 1.00 | PIK3CA (0.41) | PIK3CAAKT1MTORACACBEGFR | |
| SCHEMBL2287454 | 1.00 | PIK3CA (0.41) | PIK3CAAKT1MTORACACBEGFR | |
| SCHEMBL3396466 | 0.90 | PIK3CA (0.41) | PIK3CALRRK2MEN1KMT2AKDM4E | |
| SCHEMBL17095481 | 0.87 | KDM4E (0.41) | ACACBMEN1KMT2AKDM4EGRM5 | |
| SCHEMBL30402215 | 0.87 | KDM4E (0.41) | ACACBMEN1KMT2AKDM4EGRM5 | |
| SCHEMBL30748858 | 0.81 | KDM4E (0.44) | ACACBMEN1KMT2AKDM4EGPR119 | |
| SCHEMBL1927392 | 0.81 | DGAT1 (0.40) | PIK3CAAKT1MTORACACBEGFR | |
| SCHEMBL21443398 | 0.81 | LRRK2 (0.44) | PIK3CAACACBEGFRITKLRRK2 | |
| SCHEMBL15672731 | 0.81 | LRRK2 (0.44) | PIK3CAACACBEGFRITKLRRK2 | |
| SCHEMBL1927389 | 0.81 | DGAT1 (0.40) | PIK3CAAKT1MTORACACBEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6673811-B1 | TREATMENT OF ANXIETY, DEPRESSION, SLEEP DISORDER, ATTENTION DEFICIT DISORDER, ALZHEIMER'S DEMENTIA, OR SHORT-TERM MEMORY LOSS | NEUROGEN CORPORATION | 2004-01-06 | — | — | US | claimed |
| US-11351168-B1 | 2,4-disubstituted pyrimidines useful as kinase inhibitors | CELGENE CAR LLC (BM) | 2022-06-07 | — | — | US | disclosed |
| US-10828300-B2 | Substituted 2,4-diaminopyrimidines as kinase inhibitors | CELGENE CAR LLC (BM) | 2020-11-10 | — | — | US | disclosed |
| US-10596172-B2 | 2,4-disubstituted pyrimidines useful as kinase inhibitors | CELGENE CAR LLC (BM) | 2020-03-24 | — | — | US | disclosed |
| EP-3549934-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | Celgene CAR LLC (BM) | 2019-10-09 | — | — | EP | disclosed |
| US-20190192512-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2019-06-27 | — | — | US | disclosed |
| US-20190117650-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2019-04-25 | — | — | US | disclosed |
| EP-2519235-B1 | HETEROARYL COMPOUNDS AND USES THEREOF | CELGENE CAR LLC (BM) | 2018-11-21 | — | — | EP | disclosed |
| EP-2361248-B1 | HETEROARYL COMPOUNDS AND USES THEREOF | CELGENE CAR LLC (BM) | 2018-09-19 | — | — | EP | disclosed |
| US-10010548-B2 | 2,4-disubstituted pyrimidines useful as kinase inhibitors | CELGENE CAR LLC (BM) | 2018-07-03 | — | — | US | disclosed |
| US-20130065879-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2013-03-14 | — | — | US | disclosed |
| US-20130065899-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2013-03-14 | — | — | US | disclosed |
| US-8338439-B2 | 2,4-disubstituted pyrimidines useful as kinase inhibitors | CELGENE AVILOMICS RESEARCH, INC. (US) | 2012-12-25 | — | — | US | disclosed |
| EP-2519235-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | Avila Therapeutics, Inc. (US) | 2012-11-07 | — | — | EP | disclosed |
| EP-2361248-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | Avila Therapeutics, Inc. (US) | 2011-08-31 | — | — | EP | disclosed |
| WO-2011090760-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2011-07-28 | — | — | WO | disclosed |
| US-20100249092-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2010-09-30 | — | — | US | disclosed |
| US-20100029610-A1 | Heteroaryl Compounds and Uses Thereof | AVILA THERAPEUTICS, INC. (US) | 2010-02-04 | — | — | US | disclosed |
| WO-2009158571-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | AVILA THERAPEUTICS AND USES THEREOF (US) | 2009-12-30 | — | — | WO | disclosed |
| US-6673811-B1 | TREATMENT OF ANXIETY, DEPRESSION, SLEEP DISORDER, ATTENTION DEFICIT DISORDER, ALZHEIMER'S DEMENTIA, OR SHORT-TERM MEMORY LOSS | NEUROGEN CORPORATION | 2004-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029610-A1 | Heteroaryl Compounds and Uses Thereof | ABCG2, CYP3A43, CYP3A5 | PIK3CA 1028/4885AKT1 2747/4885MTOR 3624/4885 |
| US-20100249092-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | PIK3CA 1028/4885AKT1 2747/4885MTOR 3624/4885 |
| US-11351168-B1 | 2,4-disubstituted pyrimidines useful as kinase inhibitors | DCK, CDK2, DTYMK | PIK3CA 17/4885AKT1 227/4885MTOR 240/4885 |
| US-20190192512-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | PIK3CA 1028/4885AKT1 2747/4885MTOR 3624/4885 |
| US-20130065879-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | PIK3CA 1028/4885AKT1 2747/4885MTOR 3624/4885 |
| US-10010548-B2 | 2,4-disubstituted pyrimidines useful as kinase inhibitors | DCK, CDK2, DTYMK | PIK3CA 17/4885AKT1 227/4885MTOR 240/4885 |
| US-10828300-B2 | Substituted 2,4-diaminopyrimidines as kinase inhibitors | ABL1, DCK, ERBB2 | PIK3CA 39/4885AKT1 186/4885MTOR 224/4885 |
| US-20130065899-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | PIK3CA 1028/4885AKT1 2747/4885MTOR 3624/4885 |
| US-20190117650-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | PIK3CA 1028/4885AKT1 2747/4885MTOR 3624/4885 |
| US-10596172-B2 | 2,4-disubstituted pyrimidines useful as kinase inhibitors | DCK, CDK2, DTYMK | PIK3CA 17/4885AKT1 227/4885MTOR 240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.